The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials
Jonathan I. Silverberg(George Washington University), Jonathan Zalevsky(Nektar Therapeutics (United States)), David Rosmarin(Indiana University School of Medicine), Stephen M. Schleicher(Tennessee Oncology), Thomas Bieber(CK-CARE), Raj Chovatiya(Rosalind Franklin University of Medicine and Science), Sohail S. Chaudhry(Nektar Therapeutics (United States)), Ajay Nirula(Norwegian Womens Public Health Association), Brian L. Kotzin(Howard Hughes Medical Institute), Mary Tagliaferri(Nektar Therapeutics (United States)), Lisa A. Beck(University of Rochester Medicine), Christie Fanton(Nektar Therapeutics (United States)), Danni Yu(National Heart Lung and Blood Institute), Carsten Schmitz(Beth Israel Deaconess Medical Center), Yi Liu(Nektar Therapeutics (United States)), Melinda Gooderham(Queen's University), Joshua Levy(Centre National de la Recherche Scientifique), Takahiro Miyazaki(Nektar Therapeutics (United States))
Cited by 37
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k